Skip to main content
. 2004 Aug;24(16):7298–7311. doi: 10.1128/MCB.24.16.7298-7311.2004

FIG. 3.

FIG. 3.

Specific PKCδ kinase inhibitors and activators modulate SRF DNA binding activity. (A) In vitro kinase reactions with SRF(His)6 and kinases supplied from equal amounts of young (Y), senescent (O), or a combination of young- and old-cell nuclear extracts (Y/O) were performed in the presence of [γ-32P]ATP. Control (C) reactions with SRF but without nuclear extract were also incubated in the presence of [γ-32P]ATP (lanes 1, 5, and 9). Parallel sets of reactions were carried out in the presence of either 20 μM rottlerin (lanes 5 to 8) or 50 nM bistratene A (lanes 9 to 12), which inhibit and activate PKCδ, respectively (B). In vitro kinase reactions performed in parallel without radiolabel were used with labeled SRE EMSAs (lanes 13 to 24).

HHS Vulnerability Disclosure